A citation-based method for searching scientific literature

List of co-cited articles
811 articles co-cited >1

Times Cited
  Times     Co-cited

Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor.
R G Chirivi, A Garofalo, M J Crimmin, L J Bawden, A Stoppacciaro, P D Brown, R Giavazzi. Int J Cancer 1994

Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340.
A Price, Q Shi, D Morris, M E Wilcox, P M Brasher, N B Rewcastle, D Shalinsky, H Zou, K Appelt, R N Johnston,[...]. Clin Cancer Res 1999

Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
D R Shalinsky, J Brekken, H Zou, C D McDermott, P Forsyth, D Edwards, S Margosiak, S Bender, G Truitt, A Wood,[...]. Ann N Y Acad Sci 1999

Matrix metalloproteinase inhibitors.
S M Wojtowicz-Praga, R B Dickson, M J Hawkins. Invest New Drugs 1997

Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases.
G Taraboletti, A Garofalo, D Belotti, T Drudis, P Borsotti, E Scanziani, P D Brown, R Giavazzi. J Natl Cancer Inst 1995

Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
R Giavazzi, A Garofalo, C Ferri, V Lucchini, E A Bone, S Chiari, P D Brown, M I Nicoletti, G Taraboletti. Clin Cancer Res 1998

Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer.
G I Murray, M E Duncan, P O'Neil, W T Melvin, J E Fothergill. Nat Med 1996

Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.
T Itoh, M Tanioka, H Yoshida, T Yoshioka, H Nishimoto, S Itohara. Cancer Res 1998

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
S Wojtowicz-Praga, J Torri, M Johnson, V Steen, J Marshall, E Ness, R Dickson, M Sale, H S Rasmussen, T A Chiodo,[...]. J Clin Oncol 1998

Changing views of the role of matrix metalloproteinases in metastasis.
A F Chambers, L M Matrisian. J Natl Cancer Inst 1997

Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
V M Macaulay, K J O'Byrne, M P Saunders, J P Braybrooke, L Long, F Gleeson, C S Mason, A L Harris, P Brown, D C Talbot. Clin Cancer Res 1999

Development of matrix metalloproteinase inhibitors in cancer therapy.
M Hidalgo, S G Eckhardt. J Natl Cancer Inst 2001

Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor.
Z An, X Wang, N Willmott, S K Chander, S Tickle, A J Docherty, A Mountain, A T Millican, R Morphy, J R Porter,[...]. Clin Exp Metastasis 1997

Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin.
C L Wilson, K J Heppner, P A Labosky, B L Hogan, L M Matrisian. Proc Natl Acad Sci U S A 1997

Matrix metalloproteinase inhibitors and cancer: trials and tribulations.
Lisa M Coussens, Barbara Fingleton, Lynn M Matrisian. Science 2002

A matrix metalloproteinase expressed on the surface of invasive tumour cells.
H Sato, T Takino, Y Okada, J Cao, A Shinagawa, E Yamamoto, M Seiki. Nature 1994

Matrix metalloproteinases: biologic activity and clinical implications.
A R Nelson, B Fingleton, M L Rothenberg, L M Matrisian. J Clin Oncol 2000

Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
E K Rowinsky, R Humphrey, L A Hammond, C Aylesworth, L Smetzer, M Hidalgo, M Morrow, L Smith, A Garner, J M Sorensen,[...]. J Clin Oncol 2000

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.
S R Bramhall, A Rosemurgy, P D Brown, C Bowry, J A Buckels. J Clin Oncol 2001

Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis.
K J Newell, J P Witty, W H Rodgers, L M Matrisian. Mol Carcinog 1994

Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.
D E Gomez, D F Alonso, H Yoshiji, U P Thorgeirsson. Eur J Cell Biol 1997

Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
S Wojtowicz-Praga, J Low, J Marshall, E Ness, R Dickson, J Barter, M Sale, P McCann, J Moore, A Cole,[...]. Invest New Drugs 1996

How matrix metalloproteinases regulate cell behavior.
M D Sternlicht, Z Werb. Annu Rev Cell Dev Biol 2001

Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model.
S Hasegawa, N Koshikawa, N Momiyama, K Moriyama, Y Ichikawa, T Ishikawa, M Mitsuhashi, H Shimada, K Miyazaki. Int J Cancer 1998

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.
G Bergers, K Javaherian, K M Lo, J Folkman, D Hanahan. Science 1999

Tumor targeting with a selective gelatinase inhibitor.
E Koivunen, W Arap, H Valtanen, A Rainisalo, O P Medina, P Heikkilä, C Kantor, C G Gahmberg, T Salo, Y T Konttinen,[...]. Nat Biotechnol 1999

Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice.
N Igarashi, T Kubota, Y Otani, S W Matsuzaki, M Watanabe, T Teramoto, K Kumai, K Tamaki, K Tanzawa, T Kobayashi,[...]. Jpn J Cancer Res 1999

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.